Health Care [ 5/12 ] | Pharmaceuticals [ 33/74 ]
NASDAQ | Common Stock
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 21, 25 | -0.04 Increased by +91.12% | -0.09 Increased by +59.46% |
| Nov 7, 24 | -0.22 Increased by +40.54% | -0.09 Decreased by -144.44% |
| Aug 8, 24 | -0.04 Increased by +87.10% | -0.07 Increased by +40.03% |
| May 8, 24 | -0.23 Increased by +42.50% | -0.44 Increased by +47.73% |
| Mar 21, 24 | -0.42 Decreased by -90.91% | -0.35 Decreased by -20.00% |
| Nov 9, 23 | -0.37 Decreased by -54.17% | -0.31 Decreased by -19.35% |
| Aug 10, 23 | -0.31 Decreased by -24.00% | -0.20 Decreased by -55.00% |
| May 10, 23 | -0.40 Decreased by -81.82% | -0.34 Decreased by -17.65% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -3.34 M Increased by +50.62% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -17.46 M Decreased by -197.21% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -2.25 M Increased by +55.01% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -3.67 M Increased by +38.36% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 18.95 K Increased by +N/A% | -6.77 M Decreased by -90.34% | Decreased by -35.72 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.87 M Decreased by -60.49% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.01 M Decreased by -26.38% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -5.95 M Decreased by -73.58% | Decreased by N/A% Decreased by N/A% |